Now comes the hard question, how will the US payer system afford it?

"An August report from the nonprofit Institute for Clinical and Economic Review found that the treatment and similar gene-editing therapies for sickle cell disease would be cost-effective if priced between $1.35 million and $2.05 million. In the U.S., patients with the condition and their insurers pay on average between $1.6 million and $1.7 million for disease management over the course of a lifetime." Source: https://www.politico.com/news/2023/12/08/fda-gene-editing-th...